| INTRODUCTION

The Society for Cardiovascular Angiography and Interventions (SCAI)
Think Tank is held annually bringing together expert opinion from interventional cardiologists, administrative partners, and select members of the cardiovascular industry community in a collaborative venue. During the SCAI 2018 Scientific Session, topics in interventional cardiology felt to be relevant to the contemporary practice of the field were identified with the goals of defining the state of the field, current challenges, and future directions. By publishing the proceedings, the wider cardiovascular community can participate in this discussion and add their voice to the debate, helping SCAI proceed with specific action items in the future.
The Think Tank is a partnership between SCAI, the SCAI Emerging Leader Mentorship Program (ELM), select SCAI committees, and industry partners within the SCAI Corporate Community. We thank them for their participation in this venture.
Heart disease remains the leading cause of death within the United States, accounting for approximately 630 000 deaths in
2015,
1,2 despite 40-50% reduction in cardiovascular morbidity and mortality. 3, 4 In patients with coronary heart disease (CHD), over 40% of the decrease in death is attributable to the widespread adoption of evidence-based pharmacotherapies. 4 Yet, the witnessed progress has been attenuated by the suboptimal prescription and adherence to optimal medical therapy. Approximately half of patients with CHD do not adhere to their prescribed medical regimens, [5] [6] [7] and nonadherence has been associated with adverse clinical outcomes and increased health care costs. 8, 9 Within the Kaiser Permanente of Colorado CAD registry, nonadherence to β-blockers, statins, or angiotensin-converting enzyme (ACE) inhibitors for secondary prevention commonly occurred and was independently associated with increased risk of all-cause mortality, cardiovascular mortality, hospitalization for myocardial infarction or heart failure, and coronary revascularization. 9 In addition, low vs high adherence for secondary prevention of CHD equates to 10-18% increase in annual health care costs. 8 There is therefore an urgent unmet need for quality improvement initiatives to bolster medication adherence in patients with heart disease. Here, we will review the causes of cardiac medication nonadherence and highlight strategies that may be adopted or supported by SCAI to improve medication adherence for cardiovascular patients.
Medication adherence includes three distinct processes: (1) initiation, (2) implementation, and (3) discontinuation. 10 Medication initiation occurs when the patient fills their prescription and takes the first dose. Implementation refers to the manner by which the patient takes a medication over time as directed by the prescriber. Discontinuation refers to a patient stopping a medication for any reason, regardless of whether a health care provider was involved in the decision. 6 Breakdown of any one of these stages results in medication nonadherence and may be remediable by directed interventions. For example, after PCI with a drug-eluting stent (DES), 20% of Medicare patients do not fill prescriptions for clopidogrel within 7 days, a failure of drug initiation. 11 Implementation is limited for cardiovascular drugs as well. In patients prescribed statin therapy, less than half persistently took statin drugs as prescribed over the first year. 12 Furthermore, at 1 year after acute myocardial infarction, 55% of surviving and insured patients had discontinued β-blocker therapy. Given the impact of patient perspectives, beliefs, and motivation on medication adherence, facilitating patient engagement is a key goal. 10 Patients must feel that they are vital members of the health care Within the course of providing cardiovascular care, there is a need to identify teachable moments at which patients are primed for educational interventions (ie, discharge after myocardial infarction, after PCI, etc.). Interventions at these critical moments should not only seek to increase patient comprehension of their disease state, but also provide personalized education regarding pharmacotherapy and lifestyle modification. Counseling on behavior modification, self-care, and health maintenance can supplement educational tools provided to patients. 6 Mobile health technologies utilizing smart phones, tablets, short message service (SMS), and web-based tools are relatively low-cost methods by which to engage patients, reinforce treatment objectives and goals, and provide further patient education beyond the clinic visit or hospital discharge. 6, [17] [18] [19] Limited data suggest that such interven- Finally, the affordability of medicines and care contributes to medication nonadherence. 5, 6 Efforts to improve access to medications are vital to increasing medication adherence. Universal coverage and/or policies to ensure affordable prices for evidence-based medical regimens should be sought. Industry-sponsored co-pay cards and drug discount cards can be utilized when possible to limit out-of-pocket costs.
SCAI has a long tradition of providing patient education, and through the SCAI Political Action Committee (SCAI PAC), of advocating for policies to maximize health for patients with cardiovascular disease. Medication nonadherence has a tremendous impact on clinical outcomes and health care costs for patients with CHD. Medication adherence is therefore a priority for the Society.
| CONCLUSIONS
Identifying and discussing topics for which we need a more concrete path forward is a key goal within SCAI. The above discussions and presentations will hopefully serve to inform the cardiovascular and interventional community regarding SCAI's vision for the future directions. While in some cases, the discussion will result in a discrete action item, such as a consensus document, new advocacy goals, or specific committee or education work, in other cases the discussion will serve to broaden our understanding especially with regards to the state of consensus, or lack thereof. The group welcomes the larger interventional community's analysis of these discussions and participation in shaping the profession's future.
